Unlock instant, AI-driven research and patent intelligence for your innovation.

Process for preparing alectinib

一种艾乐替尼、化合物的技术,应用在中间体化合物的制备领域,能够解决昂贵、有毒试剂、总产率低等问题

Pending Publication Date: 2020-06-16
BEIJING FRESENIUS KABI PHARM CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] The above-mentioned three-step method for the introduction of ethyl groups has several disadvantages: it uses some expensive and toxic reagents, and the overall yield is low (about 14%)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process for preparing alectinib
  • Process for preparing alectinib
  • Process for preparing alectinib

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0137] Prepared in three steps, the compound of formula III is isolated

[0138] steps a and b

[0139]

[0140] step c

[0141]

[0142] Step a - Alkynylation: Preparation of Compound 9-(trimethylsilyl)ethynyl-6,6-dimethyl-8- (4-morpholin-4-ylpiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile (III)

[0143] In a dry Schlenk tube, the reactants were added under nitrogen in the following order: Compound IV (1.07 g, 2 mmol), PdCl 2 (PPh 3 ) (2mol%), trimethylsilylacetylene (2.5eq, 712μL), TEA (2eq, 558μL) and DMF (13mL). Close the Schlenk tube and transfer to an 80 °C oil bath. The reaction was stirred until complete conversion of compound IV (8-12 hours). The reaction mixture was cooled at room temperature, filtered on charcoal and washed with DMF (2 x 5 mL). Water (60 mL) was added to the crude reaction product to give a yellow precipitate which was filtered, washed with water (3 x 10 mL) and dried under vacuum (74% yield, 816 mg).

[0144]...

Embodiment 2

[0155] Prepared in two steps without isolating the compound of formula III

[0156]

[0157] Step a-b - Alkynylation and Cleavage: Preparation of Compound of Formula II

[0158] In a dry Schlenk tube, the reactants were added under nitrogen in the following order: Compound IV (1.07 g, 2 mmol), PdCl 2 (PPh 3 ) (2mol%), trimethylsilylacetylene (2.5eq, 712μL), TEA (2eq, 558μL) and DMF (13mL). Close the Schlenk tube and transfer to an 80 °C oil bath. The reaction was stirred until complete conversion of compound IV. The tube was removed from the oil bath and the reaction mixture was filtered on charcoal and washed with DMF (2 x 5 mL). Then MeOH (15mL) and K 2 CO 3 (3eq., 614mg) was added to the DMF solution, and stirring was continued at room temperature until the reaction was complete. Water (60 mL) was slowly added to the reaction crude product to give a yellow precipitate which was filtered, washed with methanol (3 x 10 mL) and dried under vacuum (717 mg, 1.50 mmol,...

Embodiment 3

[0162] One-pot preparation of alectinib

[0163]

[0164] In a dry Schlenk tube, the reactants were added under nitrogen in the following order: Compound IV (160 mg, 0.3 mmol), PdCl 2 (PPh 3 ) (4.3 mg, 2 mol%), trimethylsilylacetylene (106 μL, 2.5 eq.), TEA (85 μL, 2 eq.) and DMF (13 mL). Close the Schlenk tube and transfer to an 80 °C oil bath. The reaction was stirred until complete conversion of the reactants. Remove the tube from the oil bath and cool at room temperature. Under nitrogen, MeOH (1 mL) and K 2 CO 3 (125mg, 3eq.), and the reaction was stirred for 2 hours. The solution was transferred to an autoclave, and THF (4 mL) and Pd / C 10% (10 mol%, 31 mg) were added to the reaction mixture. Fill the autoclave with H at a pressure of 2.5 bar 2 And the reaction was stirred for 8 hours.

[0165] Hydrogen gas was released from the reactor, and the reaction mixture was filtered onto a pad of celite and transferred to a flask. The solvent was evaporated in vacuo. W...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a process for preparing alectinib, or a pharmaceutically acceptable salt thereof, and to related intermediates.

Description

technical field [0001] The invention relates to a method for preparing alectinib or a pharmaceutically acceptable salt thereof. The invention also relates to intermediate compounds useful in such methods and to the preparation of such intermediate compounds. Background technique [0002] Alectinib, the chemical name is 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-6,11-di Hydrogen-5H-benzo[b]carbazole-3-carbonitrile is represented by formula I [0003] [0004] Alectinib is approved as hydrochloride, which is the drug The active ingredient is intended to be taken orally in capsule form. It is an anaplastic lymphoma kinase (ALK) inhibitor indicated for the treatment of patients with non-small cell lung cancer (NSCLC). [0005] Alectinib represented by formula I and its hydrochloride are described in WO2010 / 143664. Example 366 of this PCT application describes the preparation of alectinib and its hydrochloride salt described in Scheme 1: [0006] ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D401/04C07F7/10
CPCC07D401/04C07F7/0812C07D413/14C07F7/083
Inventor W·卡布里A·托洛梅利A·徳尼西L·法拉扎诺
Owner BEIJING FRESENIUS KABI PHARM CO LTD